AFMD News and Press, Affimed N.V. From 04/09/21

All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100% There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-v...

Heidelberg, Germany, April 8, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2020 results and corporate update on Thursday, April 1...

Affimed N.V. (AFMD) and NKMax America announce that the FDA has cleared an investigational new drug application ((IND)) for Phase 1/2a dose escalation and expansion study investigating the combination of AFM24 and SNK-01 in patients suffering from tumors known to express EGFR. The primary obj...

Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. (NASDAQ: AFMD), a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) cleared an investigational new dr...

AFM24 preclinical in vivo data will be presented as a poster Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology co...

Shares of Affimed N.V. (NASDAQ: AFMD) are rising sharply on Wednesday following the company's release of a clinical update regarding one of its pipeline candidates. As of 1:40 p.m. EST, Affimed's stock was up by 15.2% after rising by as much as 20.7% earlier in the day. Affimed ...

MediciNova (MNOV) +87% on BARDA partnership for Ibudilast development.Cemtrex (CETX) +85%.Koss Corporation (KOSS) +50%.Obalon Therapeutics (OBLN) +34%.Enveric Biosciences (ENVB) +39% on agreement to acquire exclusive license for novel molecules from Diverse Biotech.MoneyGram Interna...

Affimed (AFMD) gains 19% premarket in reaction to its announcement to continue enrollment in the REDIRECT trial, which is evaluating AFM13 as a monotherapy for the treatment of relapsed or refractory CD30-positive peripheral T-cell lymphoma ((PTCL)). The decision to continue the tri...

Study will continue and combine cohorts of CD30 high and CD30 low expressing PTCL based on assessment from Independent Review Committee Objective responses observed in heavily pretreated patients in both cohorts Side effect profile similar to previously reported data Conferenc...

Affimed N.V. (AFMD) discloses following passive stake:Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen beneficially own ~5.64M shares, constituting 4.8% stake.Cubist Systematic Strategies and Mr. Cohen beneficially own 177,487 shares, constituting 0.2% stake.Stock ri...